FIRVANQ KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FIRVANQ KIT (FIRVANQ KIT).
Vancomycin is a tricyclic glycopeptide antibiotic that inhibits cell wall synthesis in susceptible bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby blocking peptidoglycan polymerization and cross-linking.
| Metabolism | Vancomycin is not significantly metabolized; it is excreted primarily unchanged in the urine via glomerular filtration. Less than 5% of an oral dose is absorbed systemically. |
| Excretion | Renal: >90% excreted unchanged in urine via glomerular filtration; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-10 days in anuric patients. Clinical context: Requires dose adjustment based on renal function. |
| Protein binding | 50-60% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.4-1.0 L/kg (0.7 L/kg average); increased in critically ill patients. Clinical meaning: Moderate distribution, primarily extracellular; does not penetrate CSF well without inflammation. |
| Bioavailability | Intravenous: 100%; Oral: <5% (negligible systemic absorption). |
| Onset of Action | Intravenous: Immediate (within minutes) for antimicrobial effect; Oral: Not absorbed systemically; local effect in GI tract. Onset of systemic effect for C. difficile not applicable via oral route. |
| Duration of Action | Intravenous: 6-12 hours depending on renal function; Oral: Local effect persists during colonic transit. Clinical notes: Duration correlates with serum levels; monitoring trough concentrations recommended. |
IV: 500 mg to 2 g every 8-12 hours (adjusted to target trough 15-20 mcg/mL for serious infections). Oral: 125 mg every 6 hours for 10-14 days (C. difficile).
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >50: usual dosing; CrCl 20-49: 500 mg-1 g every 12 hours; CrCl 10-19: 500 mg-1 g every 24-48 hours; CrCl <10: 500 mg-1 g every 72-96 hours; intermittent hemodialysis: 500 mg-1 g every 48-72 hours. |
| Liver impairment | No specific Child-Pugh adjustments; vancomycin pharmacokinetics not significantly altered by hepatic impairment. |
| Pediatric use | IV: 15-20 mg/kg/dose every 6-8 hours (every 12 hours in neonates). Oral: 40 mg/kg/day divided every 6-8 hours for C. difficile. |
| Geriatric use | Dose adjustment based on renal function; monitor trough levels; consider age-related reduced GFR; usual initial dose 500 mg-1 g every 12 hours with subsequent adjustments. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FIRVANQ KIT (FIRVANQ KIT).
| Breastfeeding | Vancomycin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4-0.5. The relative infant dose via milk is estimated to be less than 5% of the maternal weight-adjusted dose, unlikely to cause systemic effects in a term infant. However, there is a potential for alteration of gut flora and direct irritation of the infant's gastrointestinal tract. Caution is advised, especially in preterm or low-birth-weight infants. Use only if clearly needed and monitor infant for diarrhea or thrush. |
| Teratogenic Risk | Vancomycin (FIRVANQ KIT) is generally considered low risk during pregnancy. It crosses the placenta but does not demonstrate teratogenicity in animal studies. Limited human data show no increased risk of major birth defects. However, intravenous administration in the first trimester should be reserved for cases where clearly needed. In the second and third trimesters, use is generally considered safe for maternal indications, though monitoring for maternal ototoxicity and nephrotoxicity is warranted. No specific fetal risks are consistently reported. |
■ FDA Black Box Warning
Not applicable for oral vancomycin (FIRVANQ KIT is an oral solution). However, intravenous vancomycin has a black box warning for nephrotoxicity and ototoxicity, but this does not apply to the oral formulation due to minimal systemic absorption.
| Serious Effects |
Hypersensitivity to vancomycin or any component of the formulation.
| Precautions | Oral vancomycin should be used with caution in patients with inflammatory disorders of the intestinal mucosa due to potential for increased systemic absorption. Monitor renal function in patients receiving prolonged therapy or with renal impairment. Prolonged use may result in superinfection with non-susceptible organisms. Consider the risk of Clostridioides difficile infection relapse. |
Loading safety data…
| Fetal Monitoring | Maternal monitoring includes serum vancomycin trough levels to maintain therapeutic levels (typically 10-20 mcg/mL for most indications) and to avoid toxicity. Renal function (serum creatinine) and hearing (audiometry) should be assessed periodically due to potential nephrotoxicity and ototoxicity. In pregnancy, monitor for maternal hypotension during infusion. Fetal monitoring includes standard obstetrical assessments; no additional fetal monitoring specifically indicated. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data for vancomycin. It does not impact sperm or oocyte function or reproductive hormones at therapeutic doses. Available evidence suggests no impact on fertility. |